We have located links that may give you full text access.
Twenty years follow-up of a pilot/phase II-trial on the Bonn protocol for primary CNS lymphoma.
Neurology 2020 September 29
OBJECTIVE: To determine whether a fraction of patients with primary CNS lymphoma (PCNSL) had been cured by systemic and intraventricular methotrexate (MTX)- and cytarabine (AraC)-based chemotherapy (Bonn protocol) after a very long-term follow-up of nearly 20 years METHODS: Sixty-five patients (median age 62 years, range 27-75; median Karnofsky performance score 70, range 20-90) had been treated with systemic and intraventricular polychemotherapy without whole brain radiotherapy from September 1995 until December 2001. All patients still alive in 2019 were contacted and interviewed on their current life situation.
RESULTS: Median follow-up for surviving patients was 19.6 years (17.5-23.3 years). Out of 65 patients, 11 (17%) were still alive. Six of those never experienced any relapse. For the whole study population median overall survival (OS) was 4.4 years (95% CI 2.9-5.9), for patients ≤60 years 11.0 years (95% CI 4.8-17.0). The 10-year OS rate for the entire cohort was 29% and the estimated 20-year OS rate was 19%. Four late relapses were observed after 9.8, 10.3, 13.3 and 21.0 years.
CONCLUSION: At a median follow-up of 19.6 years, 17% of patients were alive and free of tumor, however, even after a response for decades an inherent risk of relapse, either systemic or cerebral, characterizes the biology of PCNSL.
CLASSIFICATION OF EVIDENCE: This work provides class III evidence, that PCNSL treatment with MTX-based polychemotherapy including intraventricular therapy is associated with long-term disease control in some patients.
RESULTS: Median follow-up for surviving patients was 19.6 years (17.5-23.3 years). Out of 65 patients, 11 (17%) were still alive. Six of those never experienced any relapse. For the whole study population median overall survival (OS) was 4.4 years (95% CI 2.9-5.9), for patients ≤60 years 11.0 years (95% CI 4.8-17.0). The 10-year OS rate for the entire cohort was 29% and the estimated 20-year OS rate was 19%. Four late relapses were observed after 9.8, 10.3, 13.3 and 21.0 years.
CONCLUSION: At a median follow-up of 19.6 years, 17% of patients were alive and free of tumor, however, even after a response for decades an inherent risk of relapse, either systemic or cerebral, characterizes the biology of PCNSL.
CLASSIFICATION OF EVIDENCE: This work provides class III evidence, that PCNSL treatment with MTX-based polychemotherapy including intraventricular therapy is associated with long-term disease control in some patients.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app